LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this open-label, single arm Phase II trial is to explore the
efficacy of BIBW 2992 defined by the objective response rate (CR, PR) as determined by RECIST
criteria in patients with advanced NSCLC Stage IIIB or IV whose tumors harbor activating
mutations within exon 18 to exon 21 of the EGFR receptor. Patients progressing or relapsing
after one prior cytotoxic chemotherapy regimen as well as chemotherapy naïve patients (only
in stage 2) will be allowed to enter into the trial.